88,387 Shares in IQVIA Holdings Inc. $IQV Bought by Ieq Capital LLC

Key Points

• Ieq Capital LLC purchased 88,387 IQVIA shares worth approximately $17.1 million in the second quarter, joining other institutions that collectively own 89.62% of the company.
• IQVIA reported quarterly earnings of $3.15 per share and revenue of $4.37 billion, exceeding analyst expectations; revenue increased 8.7% year over year. The company also authorized a $2 billion share-repurchase program.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $241.88, while IQVIA shares recently traded near their 12-month high.

Ieq Capital LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 88,387 shares of the medical research company's stock, valued at approximately $17,078,000. Ieq Capital LLC owned about 0.05% of IQVIA as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC grew its position in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company's stock worth $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in shares of IQVIA during the second quarter valued at approximately $514,000. First Trust Advisors LP increased its stake in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company's stock valued at $14,501,000 after buying an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC raised its holdings in shares of IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company's stock valued at $3,582,000 after acquiring an additional 1,155 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares of the company's stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider owned 20,999 shares of the company's stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 in the last ninety days. 1.70% of the stock is owned by company insiders.

IQVIA Stock Performance

Shares of IQV stock opened at $260.17 on Friday. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $260.40. The stock has a market cap of $42.82 billion, a PE ratio of 32.28, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company's fifty day moving average price is $213.32 and its 200-day moving average price is $187.52.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the prior year, the firm earned $2.81 EPS. The company's revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IQV. JPMorgan Chase & Co. boosted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Stifel Nicolaus raised their target price on shares of IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. TD Cowen lifted their target price on shares of IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. BMO Capital Markets increased their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. Finally, HSBC restated a "buy" rating and issued a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source